A Phase 2 interventional study of HNO Donor and Nitroglycerin (NTG) in Heart Failure, Cardiac Failure and Reduced Ventricular Ejection Fraction, sponsored by Bristol-Myers Squibb. Completed at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-27.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing cimlanod in Heart Failure — none open to participants now, none under way, none of them phase 3. cimlanod · Heart Failure.
Among the 10 studies testing cimlanod in Heart Failure, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 2, and was the 6th registered.
6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.
Browse Heart Failure studies →None of the 10 studies testing cimlanod in Heart Failure is open now. The open studies under Heart Failure, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 3 started in 2017.
This study's enrollment of 49 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.
Median enrollment 58 across the 10 interventional studies. Of the 10 that completed or were terminated, 4 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
28 studies in Heart Failure by Bristol-Myers Squibb: 1 open now, 2 under way, none of them phase 3. Of 24 finished, 6 (25%) have results posted.
Among the 28 studies in Heart Failure by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2017, is one of 7 in phase 2, and was the 15th registered.
Bristol-Myers Squibb’s Heart Failure studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing cimlanod in Heart Failure, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 28 in Heart Failure:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of BMS-986231 on systolic and diastolic parameters in patients with heart failure and low ejection fraction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
administered in a cross over design with 5-hour infusions and 5-28 day wash-out periods
Drug: HNO Donor · Drug: Nitroglycerin (NTG) · Other: Placebo
Infusion
Also known as: BMS-986231
Infusion
Infusion
Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.
Time frame: at the end of the 5-hour infusion
Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.
Time frame: at the end of the 5-hour infusion
Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV ejection fraction
Time frame: at the end of the 5-hour infusion
Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Mean LV power index
Time frame: at the end of the 5-hour infusion
Mean Diastolic Indices: E/A and E/e' Ratio at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function
Time frame: at the end of the 5-hour infusion
Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function
Time frame: at the end of the 5-hour infusion
Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV global longitudinal strain
Time frame: at the end of the 5-hour infusion
| Milestone | Sequence 1 | Sequence 2 | Sequence 3 | Sequence 4 | Sequence 5 | Sequence 6 |
|---|---|---|---|---|---|---|
| Started | 8 | 7 | 7 | 7 | 8 | 8 |
| Completed period 1 (p1) | 8 | 7 | 7 | 6 | 7 | 8 |
| Completed period 2 (p2) | 8 | 7 | 7 | 4 | 7 | 7 |
| Completed | 8 | 7 | 6 | 4 | 7 | 7 |
| Not completed | 0 | 0 | 1 | 3 | 1 | 1 |
| Withdrew: Withdrew consent due to personal reasons | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Acute bradycardia and hypotension | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Hypotension | 0 | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to placebo.
| mL/m^2 | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean Stroke Volume Index (SVI) Derived From the Velocity Time Integral at the Left Ventricular Outflow Tract (LVOT VTI) at the End of the 5-hour Infusion of BMS-986231, Versus Placebo | 29.545 ± 7.0243 | 28.721 ± 9.0174 | — |
The objective is to evaluate the effects of BMS-986231 on the left ventricular (LV) systolic function by stroke volume index (SVI) assessed by echocardiography compared to NTG.
| mL/m^2 | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean SVI Derived From LVOT VTI at the End of the 5-hour Infusion of BMS-986231, Versus NTG | — | 28.721 ± 9.0174 | 27.811 ± 7.9712 |
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV ejection fraction
| Percentage of blood pumped from the LV | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean LVEF, Computed by Simpson's Method at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG | 31.9 ± 7.15 | 32.8 ± 8.24 | 33.5 ± 7.33 |
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Mean LV power index
| watts per square meter (W/m^2) | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean Cardiac Power Index at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG | 0.4122 ± 0.14404 | 0.3427 ± 0.10463 | 0.3568 ± 0.09184 |
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function
| Ratio | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| E/A ratio | 0.80 ± 0.278 | 0.73 ± 0.270 | 0.71 ± 0.310 |
| E/e' ratio | 9.42 ± 4.102 | 7.00 ± 2.464 | 7.81 ± 2.652 |
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: Diastolic function
| cm/sec | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean Diastolic Indices: Annular e' Velocity at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG | 7.18 ± 2.467 | 8.07 ± 2.333 | 7.18 ± 2.143 |
Evaluate the effects of BMS-986231 on selected other left ventricular systolic and diastolic indices compared to placebo and NTG: LV global longitudinal strain
| Percentage of blood pumped from the LV | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Mean LV Global Longitudinal Strain, Computed Using STE at the End of the 5-hour Infusion of BMS-986231, Versus Placebo and NTG | -11.98 ± 2.860 | -11.94 ± 3.458 | -11.36 ± 3.067 |
Collected over From first dose to 30 days post last dose (approximately 3 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (PBO) | 0/40 (0%) | 1/40 (2.5%) | 2/40 (5%) |
| BMS-986231 | 0/42 (0%) | 0/42 (0%) | 12/42 (28.6%) |
| Nitroglycerin (NTG) | 0/44 (0%) | 1/44 (2.3%) | 10/44 (22.7%) |
| Event | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 1/40 | 0/42 | 0/44 |
| SyncopeNervous system disorders | 0/40 | 0/42 | 1/44 |
| Event | Placebo (PBO) | BMS-986231 | Nitroglycerin (NTG) |
|---|---|---|---|
| HeadacheNervous system disorders | 2/40 | 10/42 | 7/44 |
| HypotensionVascular disorders | 0/40 | 5/42 | 3/44 |
| Age, Categorical(Participants) | Overall Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 20 |
| >=65 years | 25 |
| Age, Continuous(Years) | Overall Participants |
|---|---|
| Mean | 63.7 ± 12.35 |
| Sex: Female, Male(Participants) | Overall Participants |
|---|---|
| Female | 8 |
| Male | 37 |
| Ethnicity (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 2 |
| Unknown or Not Reported | 43 |
| Race (NIH/OMB)(Participants) | Overall Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2017 to primary completion in May 2019, 17 months.
Results were first posted in Jul 2020, 1 year 2 months after primary completion.
Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's 17 months is below that.
Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cimlanod